Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Enliven Therapeutics Inc’s stock clocked out at $21.80, down -5.59% from its previous closing price of $23.09. In other words, the price has decreased by -$5.59 from its previous closing price. On the day, 0.66 million shares were traded.
Ratios:
To gain a deeper understanding of ELVN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.06 and its Current Ratio is at 21.06. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $37.
On December 13, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42.
On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37.H.C. Wainwright initiated its Buy rating on September 09, 2024, with a $37 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when Hohl Benjamin sold 3,000 shares for $22.55 per share. The transaction valued at 67,655 led to the insider holds 23,000 shares of the business.
Kintz Samuel bought 12,500 shares of ELVN for $288,625 on Jun 17 ’25. On Jun 13 ’25, another insider, Hohl Benjamin, who serves as the Officer of the company, bought 3,000 shares for $19.99 each.
Stock Price History:
Over the past 52 weeks, ELVN has reached a high of $30.03, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is 17.43%, while the 200-Day Moving Average is calculated to be -2.22%.
Shares Statistics:
A total of 49.04M shares are outstanding, with a floating share count of 32.23M. Insiders hold about 34.32% of the company’s shares, while institutions hold 73.72% stake in the company.
Earnings Estimates
The dynamic stock of Enliven Therapeutics Inc (ELVN) is currently attracting attention from 2 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.4 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.59 and -$1.59 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.64, with 1.0 analysts recommending between -$1.64 and -$1.64.
